Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Cross Below 200-Day Moving Average – Should You Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.62 and traded as low as $3.74. Cryo-Cell International shares last traded at $3.74, with a volume of 4,936 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Maxim Group downgraded shares of Cryo-Cell International from a “buy” rating to a “hold” rating in a research note on Monday, October 20th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Cryo-Cell International currently has a consensus rating of “Hold” and an average target price of $8.50.

Cryo-Cell International Stock Down 2.1%

The firm’s 50 day simple moving average is $4.21 and its 200-day simple moving average is $4.61. The company has a market capitalization of $29.98 million, a PE ratio of -53.14 and a beta of 0.55.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its earnings results on Wednesday, October 15th. The company reported $0.09 EPS for the quarter. The business had revenue of $7.83 million during the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.